GLP-1 · AustraliaOzempic vs Wegovy Cost in Australia 2026:
PBS and Private Prices Compared
Quick answer: July 2026
Ozempic may be PBS-subsidised for eligible people with type 2 diabetes. Wegovy for weight management is private prescription only. Actual prices vary by eligibility, dose and pharmacy.
Already prescribed? Track your injection day, dose and repeats. MediRemind.
Ozempic and Wegovy both contain semaglutide, made by Novo Nordisk. Same active ingredient, different approved uses, different maximum doses, and very different costs in Australia depending on your eligibility for the PBS. This guide gives you a straight comparison of what each actually costs and who qualifies for what.
Ozempic vs Wegovy: Key Differences
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Approved use | Type 2 diabetes management | Chronic weight management |
| Maximum approved dose | 1mg weekly in Australia | 2.4mg weekly |
| PBS listed in Australia? | Yes, for type 2 diabetes only | No, private prescription only |
| PBS price (general patient) | ~$25.00/month | Not applicable |
| PBS price (concession card) | ~$7.70/month | Not applicable |
| Private price (no PBS) | ~$300–$360/month | ~$269–$460/month by dose stage |
PBS co-payments shown are current July 2026 rates. PBS eligibility for Ozempic requires a confirmed type 2 diabetes diagnosis and authority prescribing, not all patients qualify. Private prices vary by pharmacy and dispensing fee.
The PBS Coverage Gap: The Biggest Cost Difference
Ozempic is on the Pharmaceutical Benefits Scheme for eligible type 2 diabetes patients. Patients who meet the PBS prescribing criteria pay the standard co-payment,$25.00 per month (general) or $7.70 per month (concession) as of July 2026. Eligibility depends on a confirmed type 2 diabetes diagnosis and your GP meeting authority requirements, not all patients qualify.
Wegovy is not on the PBS for weight management. All patients pay the full private price, currently approximately $269 to $460 per month depending on dose stage, regardless of Medicare or concession status.
Same active ingredient, the difference is the subsidy.
Eligible type 2 diabetes patient on PBS Ozempic: ~$25.00/month. Weight management patient on private Wegovy: ~$390–$460/month at maintenance.
Use the MediRemind PBS Cost Calculator to find your exact out-of-pocket cost for Ozempic or Wegovy based on your patient type.
Ozempic Cost in Australia in 2026
PBS price, for eligible type 2 diabetes patients
- General patients: approximately $25.00 per month
- Concession card holders: approximately $7.70 per month
- PBS Safety Net: after reaching the annual threshold, further PBS medicines cost the applicable reduced patient co-payment for the rest of the calendar year
Private prescription price, without PBS eligibility
Ozempic prescribed privately, for weight management without a diabetes diagnosis, or when PBS authority criteria are not met, attracts no subsidy. Private price per pen is typically $140–$180, meaning approximately $300–$360 per month at common doses. Prices vary between pharmacies.
Wegovy Cost in Australia in 2026
Wegovy is private-prescription only for all patients, no PBS subsidy regardless of concession status. The cost varies by dose stage: starting doses are lower, and the cost increases as the dose escalates toward maintenance. See the full Wegovy cost breakdown by dose for a complete month-by-month table.
| Dose stage | Treatment week | Approx. monthly cost (private) |
|---|---|---|
| 0.25mg, starting dose | Weeks 1–4 | ~$269 – $320 |
| 0.5mg, escalation | Weeks 5–8 | ~$269 – $340 |
| 1.0mg, escalation | Weeks 9–12 | ~$250 – $360 |
| 1.7mg, escalation | Weeks 13–16 | ~$390 – $460 |
| 2.4mg, maintenance (ongoing) | Week 17+ | ~$390 – $460 |
Private pharmacy prices sourced from Australian pharmacies July 2026. Prices vary by pharmacy and dispensing fee. Always confirm current pricing before ordering.
Who Qualifies for Each?
Ozempic at PBS price
You must have a confirmed type 2 diabetes diagnosis and your GP must meet PBS authority prescribing criteria. If weight management is also a goal, Ozempic at PBS rates is far more cost-effective than Wegovy, but it is only available on PBS for the diabetes indication.
Wegovy
Adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity (type 2 diabetes, high blood pressure, high cholesterol, sleep apnoea). A GP, endocrinologist, or telehealth weight management clinic can prescribe Wegovy.
Can You Use Ozempic for Weight Loss Instead of Wegovy?
Ozempic is sometimes prescribed off-label for weight management. In this case it is a private prescription with no PBS subsidy, costs are broadly similar to Wegovy at comparable doses. There is also a supply consideration: Ozempic has experienced shortages in Australia when weight management demand has competed with diabetes supply. During shortages, the TGA has asked prescribers to prioritise diabetes patients. Wegovy uses a separate supply chain. Discuss the appropriate option with your prescriber.
Mounjaro: The Third Option
Mounjaro (tirzepatide) targets two receptors (GLP-1 and GIP) rather than one, and has shown greater average weight loss than semaglutide in head-to-head trials. As of 1 September 2026, Mounjaro is available in Australia on private prescription, is not PBS-listed for any indication and the official listing process has ceased because the manufacturer did not proceed. See the Mounjaro dose-price guide for current published examples.
| Ozempic (PBS for diabetes) | Wegovy (private) | Mounjaro (private) | |
|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Tirzepatide |
| Monthly cost | ~$25.00 PBS / ~$300–$360 private | ~$269–$460 by dose stage | ~$350–$600 by dose |
| PBS subsidised? | Yes, diabetes only | No | No |
Keeping Your Weekly Prescription Organised
Ozempic, Wegovy, and Mounjaro are all once-weekly injections with dose escalation schedules. The weekly timing, prescribed dose stage and repeat count all need active tracking, especially when dose stages change over the first few months of treatment.
Weekly injection reminders
Set a reminder for your chosen injection day each week. MediRemind sends a push notification so your weekly schedule stays consistent.
Dose records
Record the dose your healthcare professional has instructed. Keep your current prescribed dose visible throughout escalation, from starting dose to maintenance.
Repeat tracking
MediRemind tracks how many repeats remain on your script and alerts you when you are on your last one, giving you time to book your GP.
Refill alerts
Receive a reminder before you may need to organise another supply. Avoiding gaps is important for any ongoing weekly prescription.
Frequently Asked Questions
Is Ozempic cheaper than Wegovy in Australia?
For type 2 diabetes patients on a PBS prescription, dramatically so, approximately $25.00 per month (general) versus $390–$460 per month for Wegovy at the maintenance dose. For weight loss patients using semaglutide privately without a diabetes diagnosis, the costs are broadly similar. Ozempic is not PBS-subsidised for weight management.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide. In Australia, Ozempic is approved for type 2 diabetes and has a maximum registered weekly dose of 1 mg. Wegovy is approved for chronic weight management and private-only at up to 2.4 mg weekly. The same active ingredient is used in both. The difference is the approved indication, maximum dose, and subsidy status.
Why is Wegovy more expensive than Ozempic?
Wegovy is not PBS-listed for weight management, so there is no government subsidy. Ozempic's low cost for diabetes patients comes entirely from the PBS subsidy, not because the drug itself is cheaper to produce.
Can I use Ozempic for weight loss instead of Wegovy?
Ozempic is sometimes prescribed off-label for weight loss, but as a private prescription, no PBS subsidy applies and the cost is similar to Wegovy. There have also been Ozempic shortages in Australia due to weight loss demand competing with diabetes supply. Your prescriber can advise on the appropriate option for your situation.
Will Ozempic or Wegovy get cheaper in Australia?
PBS listing of semaglutide for weight management would lower costs significantly for eligible patients. The PBAC issued a positive recommendation in November 2025 for Wegovy for a narrow patient group with established cardiovascular disease. No listing date has been confirmed as of July 2026.
Which produces more weight loss, Ozempic or Wegovy?
Both contain semaglutide. The higher maximum dose in Wegovy (2.4 mg vs 1 mg for the Australian Ozempic schedule) is associated with different treatment indications and clinical outcomes. Individual responses vary and your prescriber is best placed to advise based on your health profile.
What about Mounjaro, how does it compare?
Mounjaro (tirzepatide) targets two receptors (GLP-1 and GIP) and has shown greater average weight loss than semaglutide in head-to-head clinical trials. It is available in Australia on private prescription at broadly comparable pricing to Wegovy. As of 1 September 2026 it is not PBS-listed for any indication, and the official listing process has ceased because the manufacturer did not proceed.
How do I find out exactly what my medication will cost?
Use the MediRemind PBS Cost Calculator at https://www.mediremind.com.au/pbs-medication-cost-calculator-australia. Enter your medication name and it shows you the current PBS co-payment, private prescription price, concession rate, and Safety Net threshold, all in one place.
This article is for general information only and does not constitute medical or pharmaceutical advice. Information about PBS listings, TGA approvals and medication pricing is accurate at the time of writing and subject to change, verify current status at PBS.gov.au or TGA.gov.au before relying on it. Speak to your doctor or pharmacist before making any decisions about your medication or treatment. MediRemind is not affiliated with Novo Nordisk or any other pharmaceutical manufacturer.
References to weight management medications on this page are for general information only. MediRemind does not prescribe, supply or endorse any specific medication. Individual circumstances vary, speak to your doctor about which treatment is appropriate for you.
Already prescribed? See how to manage a weekly injection schedule.
Related guides
Already prescribed? Keep your weekly schedule organised
Keep your injection schedule, prescribed dose and repeats organised with MediRemind. 30-day trial, then a subscription, $4.99/month or $39.99/year.
Australian owned · Built in Perth · Medication data stays on your device